Your browser doesn't support javascript.
SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape.
Cele, Sandile; Karim, Farina; Lustig, Gila; San, James Emmanuel; Hermanus, Tandile; Tegally, Houriiyah; Snyman, Jumari; Moyo-Gwete, Thandeka; Wilkinson, Eduan; Bernstein, Mallory; Khan, Khadija; Hwa, Shi-Hsia; Tilles, Sasha W; Singh, Lavanya; Giandhari, Jennifer; Mthabela, Ntombifuthi; Mazibuko, Matilda; Ganga, Yashica; Gosnell, Bernadett I; Karim, Salim S Abdool; Hanekom, Willem; Van Voorhis, Wesley C; Ndung'u, Thumbi; Lessells, Richard J; Moore, Penny L; Moosa, Mahomed-Yunus S; de Oliveira, Tulio; Sigal, Alex.
  • Cele S; Africa Health Research Institute, Durban, South Africa; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Karim F; Africa Health Research Institute, Durban, South Africa; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Lustig G; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
  • San JE; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Hermanus T; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Tegally H; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa; Centre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa.
  • Snyman J; Africa Health Research Institute, Durban, South Africa; HIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, South Africa.
  • Moyo-Gwete T; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Wilkinson E; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa; Centre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa.
  • Bernstein M; Africa Health Research Institute, Durban, South Africa.
  • Khan K; Africa Health Research Institute, Durban, South Africa; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Hwa SH; Africa Health Research Institute, Durban, South Africa; Division of Infection and Immunity, University College London, London, UK.
  • Tilles SW; Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, WA, USA.
  • Singh L; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Giandhari J; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Mthabela N; Africa Health Research Institute, Durban, South Africa.
  • Mazibuko M; Africa Health Research Institute, Durban, South Africa.
  • Ganga Y; Africa Health Research Institute, Durban, South Africa.
  • Gosnell BI; Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa.
  • Karim SSA; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
  • Hanekom W; Africa Health Research Institute, Durban, South Africa; Division of Infection and Immunity, University College London, London, UK.
  • Van Voorhis WC; Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, WA, USA.
  • Ndung'u T; Africa Health Research Institute, Durban, South Africa; HIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, South Africa.
  • Lessells RJ; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Moore PL; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the
  • Moosa MS; Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa.
  • de Oliveira T; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa; Centre for Epidemic Response and In
  • Sigal A; Africa Health Research Institute, Durban, South Africa; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; Max Planck Institute for Infection Biology, Berlin, Germany. Electronic address: alex.sigal@ahri.org.
Cell Host Microbe ; 30(2): 154-162.e5, 2022 02 09.
Article in English | MEDLINE | ID: covidwho-1708092
ABSTRACT
Characterizing SARS-CoV-2 evolution in specific geographies may help predict properties of the variants that come from these regions. We mapped neutralization of a SARS-CoV-2 strain that evolved over 6 months from ancestral virus in a person with advanced HIV disease in South Africa; this person was infected prior to emergence of the Beta and Delta variants. We longitudinally tracked the evolved virus and tested it against self-plasma and convalescent plasma from ancestral, Beta, and Delta infections. Early virus was similar to ancestral, but it evolved a multitude of mutations found in Omicron and other variants. It showed substantial but incomplete Pfizer BNT162b2 escape, weak neutralization by self-plasma, and despite pre-dating Delta, it also showed extensive escape of Delta infection-elicited neutralization. This example is consistent with the notion that SARS-CoV-2 evolving in individual immune-compromised hosts, including those with advanced HIV disease, may gain immune escape of vaccines and enhanced escape of Delta immunity, and this has implications for vaccine breakthrough and reinfections.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / Antibodies, Neutralizing / Immune Evasion / Immunogenicity, Vaccine / SARS-CoV-2 / BNT162 Vaccine Type of study: Prognostic study Topics: Vaccines / Variants Limits: Adult / Animals / Female / Humans Country/Region as subject: Africa Language: English Journal: Cell Host Microbe Journal subject: Microbiology Year: 2022 Document Type: Article Affiliation country: J.chom.2022.01.005

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / Antibodies, Neutralizing / Immune Evasion / Immunogenicity, Vaccine / SARS-CoV-2 / BNT162 Vaccine Type of study: Prognostic study Topics: Vaccines / Variants Limits: Adult / Animals / Female / Humans Country/Region as subject: Africa Language: English Journal: Cell Host Microbe Journal subject: Microbiology Year: 2022 Document Type: Article Affiliation country: J.chom.2022.01.005